Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 5/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771177 | 0.83 | MAPK14 (0.60) | MAPK14TGFBR1IDO1CYP3A4KDM4E | |
| SCHEMBL5772428 | 0.81 | MAPK14 (0.54) | MAPK14TGFBR1IDO1CYP3A4KDM4E | |
| SCHEMBL5772627 | 0.80 | MAPK14 (0.74) | MAPK14 | |
| SCHEMBL5775369 | 0.74 | MAPK14 (0.72) | MAPK14TGFBR1 | |
| SCHEMBL6183892 | 0.70 | TGFBR1 (0.54) | MAPK14TGFBR1IDO1CYP3A4 | |
| SCHEMBL6183193 | 0.70 | TGFBR1 (0.51) | MAPK14TGFBR1CYP3A4 | |
| SCHEMBL16331148 | 0.69 | RET (0.66) | MAPK14KDM4ENT5E | |
| SCHEMBL5774046 | 0.68 | MAPK14 (0.57) | MAPK14TGFBR1KDM4EMAPT | |
| SCHEMBL5776097 | 0.68 | MAPK14 (0.73) | MAPK14 | |
| SCHEMBL5773894 | 0.67 | MAPK14 (0.62) | MAPK14IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370559-B1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6696464-B2 | POTENT INHIBITORS OF MAP KINASES, PREFERABLY P38 KINASE; USEFUL IN TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, REPERFUSION OR ISCHEMIA IN STROKE OR HEART ATTACK | PFIZER INC | 2004-02-24 | — | — | US | disclosed |
| EP-1370559-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | PFIZER INC. | 2003-05-22 | — | — | US | disclosed |
| WO-2002072579-A1 | TRIAZOLOPYRIDINES AS ANTI-INFLAMMATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096838-A1 | Novel triazolo-pyridines anti-inflammatory compounds | MAPK1, CNKSR1, JAK1 | MAPK14 15/4885TGFBR1 1408/4885IDO1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.